Stephens raises Glaukos price target to $80, says guidance conservative ‘again’

Stephens analyst Chris Cooley raised his price target on Glaukos shares to $80 from $70, stating that he believes the company’s annual revenue guidance appears conservative “once again” given his view that iStent inject can not only increase existing user utilization but also expand the market while modestly increasing pricing. The analyst, who now assumes Glaukos will achieve GAAP profitability in calendar 2020, keeps an Overweight rating on the stock.

https://thefly.com/landingPageNews.php?id=2872256